Drug – bio-affecting and body treating compositions – Designated organic active ingredient containing – Peptide containing doai
Reissue Patent
2006-04-04
2006-04-04
Weddington, Kevin E. (Department: 1614)
Drug, bio-affecting and body treating compositions
Designated organic active ingredient containing
Peptide containing doai
C514S484000, C514S866000
Reissue Patent
active
RE039055
ABSTRACT:
The invention provides an analogue of a pharmaceutical active whose molecular weight is less than 25,000 Daltons, the analogue comprising a pharmaceutical active whose molecular weight is less than 25,000 Daltons covalently linked to a pendant molecular group wherein as a result of the administration of the composition to the human or animal body an active complex having a molecular weight of 25,000 Daltons or greater is present in the human or animal circulatory system. The analogue is hepatoselective when administered to the circulatory system. Preferably the analogue is an insulin analogue comprising an insulin or functional equivalent thereof covalently linked to the pendant molecular group wherein the active complex is an insulin complex. Such an insulin analogue may be used in a method of insulin replacement therapy.
REFERENCES:
patent: 3528960 (1970-09-01), Haas
patent: 5268453 (1993-12-01), Andy et al.
patent: 5854208 (1998-12-01), Jones et al.
patent: 6342225 (2002-01-01), Jones et al.
patent: 0242416 (1987-10-01), None
patent: 0 678 522 (1995-10-01), None
patent: 0 383 472 (1996-02-01), None
patent: 0 709 395 (1996-05-01), None
patent: 0 712 861 (1996-05-01), None
patent: 0 712 862 (1996-05-01), None
patent: 0 747 390 (1996-12-01), None
patent: 0 747 391 (1996-12-01), None
patent: 01254699 (1989-11-01), None
patent: 9012814 (1990-11-01), None
patent: 9112817 (1991-09-01), None
patent: 9200322 (1992-01-01), None
patent: 9215611 (1992-09-01), None
patent: 9507931 (1995-03-01), None
patent: WO 99/65941 (1999-12-01), None
patent: WO 02/04515 (2002-01-01), None
Windholz et al., The Merck Index, Tenth Edition (1983), pp. 723 and 724, abstract No. 4866.
Shojaee-Moradie et al., “Novel Hepatoselective Insulin Analogues: Studies with Covalently Linked Thyroxyl-insulin Complexes,”Diabetic Medicine, vol. 15, (1998), pp. 928-936.
Shojaee-Moradie et al., “Effects of a hepatoselective insulin analogue in normal subjects,”Diabetic Medicine, vol. 15, (1998), (Suppl. 2), 53, A1.
Telfer et al, “The effects of thyroid hormone binding proteins on insulin receptor binding of thyroxyl-insulin analogues in vitro,”Diabetic Medicine, vol. 15, (1998), (Suppl 2), S5, A10.
Shojaee-Moradie et al., “Novel Hepatoselective Insulin Analog: Studies with a covalently linked thyroxyl-insulin complex in humans,”Diabetes Care, vol. 23, No. 8, (Aug. 2000), pp. 1124-1129.
Kurtzhals et al., “Albumin binding of insulins acylated with fatty acids: characterization of the ligand-protein interaction and correlation between binding affinity and timing of the insulin effect in vivo,”Biochem J., (1995), vol. 312, pp. 725-731.
Myers et al., “Acylation of Human Insulin With Palmitic Acid Extends the Time Action of Human Insulin in Diabetic Dogs,”Diabetics, vol. 46, (Apr. 1997), 637-642.
Asada et al., “Absorption Characteritics of Chemically Modified-Insulin Derivatives with Various Fatty Acids in the Small and Large Intestine,”J. Pharm. Sci., vol. 84, No. 6, (Jun. 1995), pp. 682-687.
Polzer, et al, “Inhibition of benzol[a]pyrene metabolism by insulin, FITC-insulin and an FITC-insulin-antibody conjugate in the human hepatoma cell line HepG2,”Chemico-Biological Interactions, vol. 97, (1995), pp. 307-318.
Schaffer, “A model for insulin binding to the insulin receptor,”Eur. J. Biochem., (1994), vol. 221, pp. 1127-1132.
Ziegler et al., “Insulin Binding to Human Cultured Lymphocytes Measured by Flow Cytometry Using Three Ligands,”Cytometry, (1994), vol. 16, pp. 339-345.
Matkhanov et al., “Cytotoxic Effect of Free Bleomycin A5-Iron (II) Complex and its Conjugates with Concanavalin, A, Insulin and Colcitonin on Mouse thymocytes,”Biochem. Biophys. Res. Comm., (Nov. 1993), vol. 197, No. 1, pp. 85-91.
Fabry et al., “Design and Synthesis of a Novel Biotinylated Photoreactive Insulin for Receptor Analysis,”Biological Chemistry Hoppe-Seyler, (Mar. 1992), vol. 373, No. 3, pp. 143-150.
Ikeda et al., “Effect of Diabetes on Triiodothyronine and Reverse Triiodothyronine Production in the Perfused Rat Liver and Kidney,”Diabetes, (Jul. 1985), vol. 34, pp. 647-652.
Chemical Abstracts (99:116795m) Kaliman ct al. (1983). J.
J. Brange et al., Diabetes Care, vol. 13, No. 9 “Monomeric Insulins and Their Experimental and Clinical Implications” Sep. 9, 1990, pp. 923-925.
Ronald S. Spangler, “Selective insulinization of liver in conscious diabetic dogs”, Am. J. Physiol. 249 (Endocrinal. Metab. 12) pp. E152-159 (1985).
J. Morkussen et al., Soluble, fatty acid acylated insulins bind to albumin and show protracted action in pigs, No. 262, pp. 002-009.
Journal of Controlled Release, (1992), pp. 179-188, Trials of Lipid modification of piptide hormones for intestinal delivery.
Pharmaceutical Research, vol. 6, No. 2, (1989), Synthesis of Palmitoyl Derivatives of Insulin and Their Biological Activities.
Proceedings of the Second International Insulin Symposium Aachen, Germany, Sep. 4-7, 1979, Insulin Chemistry, Structure and Function of Insulin and Related Hormones.
F. Shojaee-Maradi, et al., “Convalent Insulin Dimers Are Hepatoselective”, Abstract, Medical and Scientific Section, Apr. 13-15, 1989.
Snyder, S. M. et al. “The Binding of Thyroid Hormone Analogues to to Thyrozine-Binding Globulin (TBG)”, in Thyroid Research (Robbin J. and Braveman L. E. eds.) (1976) pp. 297 to 299.
Snyder, S. M. et al. (1976) Binding of Thyroid Hormones and their Analogues to Thyroxin-Binding Globulin in Human Serum, J. Biol. Chem. 251 (21), 6489 to 6494.
Robbins, J. et al. “Plasma Transport of Thyroid Hormones” from Thyroid Hormone Metabolism (Hennemann, G. ed) 1986, 3 to 38.
Brandenburg Dietrich
Eckey Heike
Jones Richard Henry
Schuttler Achim
Shojaee-Moradi Fariba
BTG International Limited
Weddington Kevin E.
LandOfFree
Hepatoselective pharmaceutical actives does not yet have a rating. At this time, there are no reviews or comments for this patent.
If you have personal experience with Hepatoselective pharmaceutical actives, we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Hepatoselective pharmaceutical actives will most certainly appreciate the feedback.
Profile ID: LFUS-PAI-O-3604879